Remove 2024 Remove Heart Dysfunction Remove Heart Failure
article thumbnail

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

DAIC

mtaschetta-millane Thu, 07/11/2024 - 10:53 July 11, 2024Heart Test Laboratories, Inc. Low-cost testing for heart failure has not been readily available for front-line physicians.

article thumbnail

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

DAIC

milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Ashwin Ravichandran and Scott Hittinger.

Pulmonary 110
article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar.

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

article thumbnail

Abstract 4146828: Downregulation of ADAR1 Attenuates Hypothermic Cardioprotection in Aged Donor Hearts During Transplantation

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.